OBT: WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics
WuXi Biologics formed a $450 million partnership with England's Oxford BioTherapeutics to develop five novel bispecific antibodies including a PDL1 molecule using its WuXiBody Platform. OBT says the bispecifics will combine two secondgen immunon...
Read full article »Est. Annual Revenue
Est. Employees
Founder & CEO
Christian Rohlff
OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more
